Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0948265 (metabolic syndrome)
 24,271 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

There are many studies with respect to the age-related change of the characteristics of beat-to-beat heart rate variability (HRV), reflected by cardiac autonomic control, especially focusing on adulthood (i.e., aging related to the incidence of metabolic syndrome) in Japanese individuals. However, it is not still clear how basic control matures during childhood. This study was, therefore, designed to explore the HRV characteristics of pre- and post-adolescent Japanese, in a cross-sectional manner. Resting HRV data was recorded in a relaxing supine position from 136 healthy individuals between 8 and 20 years (48 boys between 8 and 14 years; 88 girls between 8 and 20 years) who were instructed to breathe periodically (0.25 Hz). Frequency-domain analysis (i.e., the spectral analysis based on an autoregressive model) of short-term, stationary R-R intervals was performed to evaluate the low- (LF; below 0.15 Hz) and high- (HF; 0.15-0.40 Hz) frequency powers. The HF to total power represents the vagal control of heart rate (PNS indicator), and the ratio of LF to HF (LF/HF) is considered to relate to the sympathetic modulations (SNS indicator). Both PNS and SNS indices had substantially no effect from age and/or gender in the range between 8 and 20 years. In conclusion, the control of the cardiac autonomic nervous system in Japanese seems already to be compatible with that in adulthood before approximately 10 years. In other word, the cardiac autonomic modulation would presumably be maturated before the age of approximately 7-8 years, though further research is awaited.
 ...
PMID:Autonomic nervous activities assessed by heart rate variability in pre- and post-adolescent Japanese. 2000 74

Autotaxin (ATX) is a soluble extracellular enzyme that is abundant in mammalian plasma and cerebrospinal fluid (CSF). It has two known enzymatic activities, acting as both a phosphodiesterase and a phospholipase. The majority of its biological effects have been associated with its ability to liberate lysophosphatidic acid (LPA) from its substrate, lysophosphatidylcholine (LPC). LPA has diverse pleiotropic effects in the central nervous system (CNS) and other tissues via the activation of a family of six cognate G protein-coupled receptors. These LPA receptors (LPARs) are expressed in some combination in all known cell types in the CNS where they mediate such fundamental cellular processes as proliferation, differentiation, migration, chronic inflammation, and cytoskeletal organization. As a result, dysregulation of LPA content may contribute to many CNS and PNS disorders such as chronic inflammatory or neuropathic pain, glioblastoma multiforme (GBM), hemorrhagic hydrocephalus, schizophrenia, multiple sclerosis, Alzheimer's disease, metabolic syndrome-induced brain damage, traumatic brain injury, hepatic encephalopathy-induced cerebral edema, macular edema, major depressive disorder, stress-induced psychiatric disorder, alcohol-induced brain damage, HIV-induced brain injury, pruritus, and peripheral nerve injury. ATX activity is now known to be the primary biological source of this bioactive signaling lipid, and as such, represents a potentially high-value drug target. There is currently one ATX inhibitor entering phase III clinical trials, with several additional preclinical compounds under investigation. This review discusses the physiological and pathological significance of the ATX-LPA-LPA receptor signaling axis and summarizes the evidence for targeting this pathway for the treatment of CNS diseases.
 ...
PMID:Pleotropic Roles of Autotaxin in the Nervous System Present Opportunities for the Development of Novel Therapeutics for Neurological Diseases. 3136 25